Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

J.P. Morgan Sticks to Its Sell Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Tipranks - Tipranks - Sat Jan 24, 1:52AM CST

In a report released today, David Adlington from J.P. Morgan maintained a Sell rating on Fresenius Medical Care AG & Co. KGaA, with a price target of €37.40.

Claim 50% Off TipRanks Premium

According to TipRanks, Adlington is an analyst with an average return of -5.9% and a 42.09% success rate. Adlington covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care AG & Co. KGaA, Siemens Healthineers AG, and Fresenius SE & Co. KGaA.

In addition to J.P. Morgan, Fresenius Medical Care AG & Co. KGaA also received a Sell from UBS’s Graham Doyle in a report issued on January 14. However, on January 21, Kepler Capital maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA (LSE: 0H9X).

See today’s best-performing stocks on TipRanks >>

0H9X market cap is currently €10.45B and has a P/E ratio of 14.94.

Read More on GB:0H9X:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).